Advertisement

Drugs

, Volume 63, Issue 2, pp 139–152 | Cite as

The Pleiotropic Effects of HMG-CoA Reductase Inhibitors

Their Role in Osteoporosis and Dementia
Leading Article

Abstract

HMG-CoA reductase is the rate-limiting enzyme for cholesterol synthesis and its inhibition exerts profound effects on cellular metabolism. Inhibitors of this enzyme are used in clinical practice to lower plasma cholesterol levels and are commonly collectively referred to as ‘statins’. A number of in vitro, in vivo animal, and clinical studies suggest that properties of statins other than cholesterol lowering may be of biological importance. These diverse properties are often referred to as ‘pleiotropic’ and suggest that statins may affect a number of diseases of ageing. In this article we review the biological plausibility and clinical evidence of a role for statins in modulating two diseases of ageing: osteoporosis and dementia (including Alzheimer’s disease). In both diseases, there is a sound cellular and laboratory basis for a plausible therapeutic effect of statins. In the case of osteoporosis, there are conflicting data regarding clinical benefit, with both negative and positive results reported. In particular, secondary analyses of randomised, controlled studies have shown no reduction of fracture risk by statins. In the case of dementia there are fewer clinical studies but there is clear anticipated benefit in macrovascular dementias attributable to statin-mediated reduction of the risk of stroke. Overall, there are a lack of prospective, placebo-controlled, randomised data testing statins and modulation of the risk of osteoporosis-related fracture or of clinical dementia, where these are primary outcomes. Until such data are available, the use of statins appears promising but cannot be recommended as a primary therapeutic modality for either condition.

Keywords

Bone Mineral Density Dementia Statin Simvastatin Pravastatin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

Professors J. Kril, D. LeCouteur and M. Seibel are thanked for many helpful discussions.

Dr. Kritharides is a member of the Australian Scientific Advisory Committee for rosuvastatin (Astra-Zeneca), and has given invited presentations at scientific symposia convened or supported by Bristol Myer Squibb, Astra Zeneca, and Merck Sharp and Dohme.

References

  1. 1.
    Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232(4746): 34–47PubMedCrossRefGoogle Scholar
  2. 2.
    Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344 3–9Google Scholar
  3. 3.
    Sacks FM, Tonkin AM, Shepherd J, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation. 2000; 102(16): 1893–900PubMedCrossRefGoogle Scholar
  4. 4.
    Watts GF, Burke V. Lipid-lowering trials in the primary and secondary prevention of coronary heart disease: new evidence, implications and outstanding issues. Curr Opin Lipidol 1996; 7(6): 341–55PubMedCrossRefGoogle Scholar
  5. 5.
    Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21(11): 1712–9PubMedCrossRefGoogle Scholar
  6. 6.
    Gotto AM Jr, Farmer JA. Pleiotropic effects of statins: do they matter? Curr Opin Lipidol 2001; 12(4): 391–4CrossRefGoogle Scholar
  7. 7.
    Comparato C, Altana C, Bellosta S, et al. Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction? Nutr Metab Cardiovasc Dis 2001; 11(5): 328–43PubMedGoogle Scholar
  8. 8.
    Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998; 279(20): 1643–50PubMedCrossRefGoogle Scholar
  9. 9.
    LaRosa JC. Pleiotropic effects of statins and their clinical significance. Am J Cardiol 2001; 88(3): 291–3PubMedCrossRefGoogle Scholar
  10. 10.
    Aikawa M, Rabkin E, Okada Y, et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation 1998; 97(24): 2433–44PubMedCrossRefGoogle Scholar
  11. 11.
    Yamamoto A, Harada-Shiba M, Kawaguchi A, et al. Apheresis technology for prevention and regression of atherosclerosis. Ther Apher 2001; 5(4): 221–5PubMedCrossRefGoogle Scholar
  12. 12.
    Mellwig KP, Baller D, Gleichmann U, et al. Improvement of coronary vasodilatation capacity through single LDL apheresis. Atherosclerosis 1998; 139(1): 173–8PubMedCrossRefGoogle Scholar
  13. 13.
    Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343(6257): 425–30PubMedCrossRefGoogle Scholar
  14. 14.
    Glomset JA, Farnsworth CC. Role of protein modification reactions in programming interactions between ras-related GTPases and cell membranes. Annu Rev Cell Biol 1994; 10: 181–205PubMedCrossRefGoogle Scholar
  15. 15.
    Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors: similarities and differences. Clin Pharmacokinet 1997; 32(5): 403–25PubMedCrossRefGoogle Scholar
  16. 16.
    Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 1998; 19(1): 26–37PubMedCrossRefGoogle Scholar
  17. 17.
    Bonn V, Cheung RC, Chen B, et al. Simvastatin, an HMG-CoA reductase inhibitor, induces the synthesis and secretion of apolipoprotein AI in HepG2 cells and primary hamster hepatocytes. Atherosclerosis 2002; 163(1): 59–68PubMedCrossRefGoogle Scholar
  18. 18.
    Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999; 84(3): 413–28PubMedCrossRefGoogle Scholar
  19. 19.
    Chong PH, Seeger JD, Franklin C. Clinically relevant differences between the statins: implications for therapeutic selection. Am J Med 2001; 111(5): 390–400PubMedCrossRefGoogle Scholar
  20. 20.
    Warwick MJ, Dane AL, Schneck DW, et al. Single- and multiple-dose pharmacokinetics and safety of the new HMG CoA-reductase inhibitor. Atherosclerosis 2000; 151: 39, Abstract P19: W6CrossRefGoogle Scholar
  21. 21.
    Martin PD, Dane AL, Schneck DE, et al. Disposition of new HMG-CoA reductase inhibitor ZD4522 following dosing in healthy subjects [abstract 48]. J Clin Pharmacol 2000; 40: 1056Google Scholar
  22. 22.
    Buckett L, Ballard P, Davidson R, et al. Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells. Atherosclerosis 2000; 151: 41CrossRefGoogle Scholar
  23. 23.
    Sabia H, Prasad P, Smith HT, et al. Safety, tolerability, and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolemia. J Cardiovasc Pharmacol 2001; 37(5): 502–11PubMedCrossRefGoogle Scholar
  24. 24.
    McCormick AD, McKillop D, Butters CJ, et al. ZD4522-An HMG CoA reductase inhibitor free of metabolically mediated drug interaction: metabolic studies in human in vitro systems. Chicago (IL): American College of Clinical Pharmacology, 2000Google Scholar
  25. 25.
    Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100(3): 230–5Google Scholar
  26. 26.
    Le Couteur DG, Cogger VC, Markus AMA, et al. Pseudocapiilarization and associated energy limitation in the aged rat liver. Hepatology 2001; 33: 537–43PubMedCrossRefGoogle Scholar
  27. 27.
    Davidson MH. Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. Expert Opin Investig Drugs. 2002; 11(1): 125–41CrossRefGoogle Scholar
  28. 28.
    Lips P. Epidemiology and predictors of fractures associated with osteoporosis. Am J Med 1997; 103(2A): 3S–8S; discussion 8S-11SPubMedCrossRefGoogle Scholar
  29. 29.
    Johnell O. The socioeconomic burden of fractures: today and in the 21st century. Am J Med 1997; 103(2A): 20S–25S; discussion 25S-6SPubMedCrossRefGoogle Scholar
  30. 30.
    van Daele PL, Seibel MJ, Burger H, et al. Case-control analysis of bone resorption markers, disability, and hip fracture risk: the Rotterdam study. BMJ 1996; 312(7029): 482–3PubMedCrossRefGoogle Scholar
  31. 31.
    Garnero P, Sornay-Rendu E, Chapuy MC, et al. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 1996; 11(3): 337–49PubMedCrossRefGoogle Scholar
  32. 32.
    Garnero P, Sornay-Rendu E, Claustrat B, et al. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000; 15(8): 1526–36PubMedCrossRefGoogle Scholar
  33. 33.
    Tintut Y, Demer LL. Recent advances in multifactorial regulation of vascular calcification. Curr Opin Lipidol 2001; 12(5): 555–60PubMedCrossRefGoogle Scholar
  34. 34.
    Burnett JR, Vasikaran SD. Cardiovascular disease and osteoporosis: is there a link between lipids and bone? Ann Clin Biochem 2002; 39 (Pt 3): 203–10PubMedCrossRefGoogle Scholar
  35. 35.
    Hak AE, Pols HA, van Hemert AM, et al. Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study. Arterioscler Thromb Vasc Biol 2000; 20(8): 1926–31PubMedCrossRefGoogle Scholar
  36. 36.
    Parhami F, Morrow AD, Balucan J, et al. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiationL: a possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler Thromb Vasc Biol 1997; 17(4): 680–7PubMedCrossRefGoogle Scholar
  37. 37.
    Parhami F, Tintut Y, Ballard A, et al. Leptin enhances the calcification of vascular cells: artery wall as a target of leptin. Circ Res 2001; 88(9): 954–60PubMedCrossRefGoogle Scholar
  38. 38.
    Pfeilschifter J, Koditz R, Pfohl M, et al. Changes in pro-inflammatory cytokine activity after menopause. Endocr Rev 2002; 23(1): 90–119PubMedCrossRefGoogle Scholar
  39. 39.
    Ormarsdottir S, Ljunggren O, Mallmin H, et al. Inverse relationship between circulating levels of leptin and bone mineral density in chronic liver disease. J Gastroenterol Hepatol 2001; 16(12): 1409–14PubMedCrossRefGoogle Scholar
  40. 40.
    Amling M, Pogoda P, Beil FT, et al. Central control of bone mass: brainstorming of the skeleton. Adv Exp Med Biol 2001; 496: 85–94PubMedCrossRefGoogle Scholar
  41. 41.
    Wallace AM, McMahon AD, Packard CJ, et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2001; 104(25): 3052–6PubMedCrossRefGoogle Scholar
  42. 42.
    Crane SK. Genetic control of bone remodelling-insights from a rare disease. N Engl J Med 2002; 347: 210–2CrossRefGoogle Scholar
  43. 43.
    Chan GK, Duque G. Age-related bone loss: old bone, new facts. Gerontology 2002; 48(2): 62–71PubMedCrossRefGoogle Scholar
  44. 44.
    Treloar V. Bisphosphonates and osteoporosis. N Engl J Med 2002; 346(26): 2088–9PubMedCrossRefGoogle Scholar
  45. 45.
    Maricic M, Adachi JD, Sarkar S, et al. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 2002; 162(10): 1140–3PubMedCrossRefGoogle Scholar
  46. 46.
    Rosen CJ, Bilezikian JP. Clinical review 123: anabolic therapy for osteoporosis. J Clin Endocrinol Metab 2001; 86(3): 957–64PubMedCrossRefGoogle Scholar
  47. 47.
    Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002; 359(9322): 2018–26PubMedCrossRefGoogle Scholar
  48. 48.
    Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999; 286 (5446): 1946–9CrossRefGoogle Scholar
  49. 49.
    Sugiyama M, Kodama T, Konishi K, et al. Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem Biophys Res Commun. 2000; 271(3): 688–92PubMedCrossRefGoogle Scholar
  50. 50.
    van Beek E, Lowik C, van der Pluijm G, et al. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone expiants in vitro: a clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res 1999; 14(5): 722–9CrossRefGoogle Scholar
  51. 51.
    Luckman SP, Hughes DE, Coxon FP, et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998; 13(4): 581–9PubMedCrossRefGoogle Scholar
  52. 52.
    Chan MH, Mak TW, Chiu RW, et al. Simvastatin increases serum osteocalcin concentration in patients treated for hyper-cholesterolaemia. J Clin Endocrinol Metab 2001; 86(9): 4556–9PubMedCrossRefGoogle Scholar
  53. 53.
    Chung YS, Lee MD, Lee SK, et al. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab 2000; 85(3): 1137–42PubMedCrossRefGoogle Scholar
  54. 54.
    Hsia J, Morse M, Levin V. Effect of simvastatin on bone markers in osteopenic women: a placebo-controlled, dose-ranging trial [ISRCTN85429598]. BMC Musculoskelet Disord 2002; 3(1): 7PubMedCrossRefGoogle Scholar
  55. 55.
    Edwards CJ, Hart DJ, Spector TD. Oral statins and increased bone mineral density in post menopausal women. Lancet 2000; 355: 2218–9PubMedCrossRefGoogle Scholar
  56. 56.
    Watanabe S, Fukumoto S, Takeuchi Y, et al. Effects of 1 year treatment with fluvastatin or pravastatin on bone. Am J Med 2001; 110: 584–7PubMedCrossRefGoogle Scholar
  57. 57.
    Chan KA, Andrade SE, Boles M, et al. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 2000; 355(9222): 2185–8PubMedCrossRefGoogle Scholar
  58. 58.
    Meier CR, Schlienger RG, Kraenzlin ME, et al. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000; 283(24): 3205–10PubMedCrossRefGoogle Scholar
  59. 59.
    van Staa TP, Wegman S, de Vries F, et al. Use of statins and risk of fractures. JAMA 2001; 285(14): 1850–5PubMedCrossRefGoogle Scholar
  60. 60.
    Wang PS, Solomon DH, Mogun H, et al. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 2000; 283(24): 3211–6PubMedCrossRefGoogle Scholar
  61. 61.
    Bauer DC, Mundy GR, Jamal SA, et al. Statin use, bone mass and fracture: an analysis of two prospective studies [abstract]. J Bone Miner Res 1999; 14: S179CrossRefGoogle Scholar
  62. 62.
    Reid IR, Hague W, Emberson J, et al. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised control trial. Lancet 2001; 357: 509–12PubMedCrossRefGoogle Scholar
  63. 63.
    Pedersen TR, Kjekshus J. Statin drugs and the risk of fracture. 4S Study Group. JAMA 2000; 284(15): 1921–2Google Scholar
  64. 64.
    Heart Protection Study Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20356 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22CrossRefGoogle Scholar
  65. 65.
    Knopman DS. An overview of common non-Alzheimer dementias. Clin Geriatr Med 2001; 17: 281–301PubMedCrossRefGoogle Scholar
  66. 66.
    Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer’s disease in a community population of older persons: higher than previously reported. JAMA 1989; 262(18): 2551–6PubMedCrossRefGoogle Scholar
  67. 67.
    Kril JJ, Halliday GM. Alzheimer’s disease: its diagnosis and pathogenesis. Int Rev Neurobiol 2001; 48: 167–217PubMedCrossRefGoogle Scholar
  68. 68.
    Esiri MM, Wilcock GK, Morris JH. Neuropathological assessment of the lesions of significance in vascular dementia. J Neurol Neurosurg Psychiatry 1997; 63: 749–53PubMedCrossRefGoogle Scholar
  69. 69.
    Jagust W. Untangling vascular dementia. Lancet 2001; 358: 2097–8PubMedCrossRefGoogle Scholar
  70. 70.
    Henon H, Durieu I, Guerouaou D, et al. Poststroke dementia: incidence and relationship to prestroke cognitive decline. Neurology 2001; 57(7): 1216–22PubMedCrossRefGoogle Scholar
  71. 71.
    Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335 (14): 1001–9CrossRefGoogle Scholar
  72. 72.
    White HD, Simes RJ, Anderson NE, et al. Pravastatin therapy and the risk of stroke. N Engl J Med. 2000; 343(5): 317–26PubMedCrossRefGoogle Scholar
  73. 73.
    Yip CM, Elton EA, Darabie AA, et al. Cholesterol, a modulator of membrane-associated Abeta-fibrillogenesis and neurotoxicity. J Mol Biol 2001; 311(4): 723–34PubMedCrossRefGoogle Scholar
  74. 74.
    Mori T, Paris D, Town T, et al. Cholesterol accumulates in senile plaques of Alzheimer disease patients and in transgenic APP(SW) mice. J Neuropathol Exp Neurol 2001; 60(8): 778–85PubMedGoogle Scholar
  75. 75.
    Kakio A, Nishimoto SI, Yanagisawa K, et al. Cholesterol-dependent formation of GM1 ganglioside-bound amyloid beta-protein, an endogenous seed for Alzheimer amyloid. J Biol Chem 2001; 276(27): 24985–90PubMedCrossRefGoogle Scholar
  76. 76.
    Sparks DL, Scheff SW, Hunsaker JC 3rd, et al. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 1994; 126(1): 88–94PubMedCrossRefGoogle Scholar
  77. 77.
    Sparks DL. Coronary artery disease, hypertension, ApoE, and cholesterol: a link to Alzheimer’s disease? Ann N Y Acad Sci 1997; 826: 128–46PubMedCrossRefGoogle Scholar
  78. 78.
    Poirier J, Delisle MC, Quirion R, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci USA 1995; 92(26): 12260–4PubMedCrossRefGoogle Scholar
  79. 79.
    Petrovitch H, White LR, Izmirilian G, et al. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia aging Study. Neurobiol Aging 2000; 21(1): 57–62CrossRefGoogle Scholar
  80. 80.
    Bruce DG, Harrington N, Davis WA, et al. Dementia and its associations in type 2 diabetes mellitus: the Fremantle Diabetes Study. Diabetes Res Clin Pract 2001; 53(3): 165–72PubMedCrossRefGoogle Scholar
  81. 81.
    Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ 2001; 322(7300): 1447–51PubMedCrossRefGoogle Scholar
  82. 82.
    Dietschy JM, Turley SD. Cholesterol metabolism in the brain. Curr Opin Lipidol 2001; 12(2): 105–12PubMedCrossRefGoogle Scholar
  83. 83.
    Papassotiropoulos A, Lutjohann D, Bagli M, et al. 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J Psychiatr Res 2002; 36(1): 27–32PubMedCrossRefGoogle Scholar
  84. 84.
    Locatelli S, Lutjohann D, Schmidt HH, et al. Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain. Arch Neurol 2002; 59(2): 213–6PubMedCrossRefGoogle Scholar
  85. 85.
    Fassbender K, Simons M, Bergmann C, et al. Simvastatin strongly reduces levels of Alzheimer’s disease beta — amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 2001; 98(10): 5856–61PubMedCrossRefGoogle Scholar
  86. 86.
    Endres M, Laufs U, Huang Z, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1998; 95(15): 8880–5PubMedCrossRefGoogle Scholar
  87. 87.
    Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998; 273(37): 24266–71PubMedCrossRefGoogle Scholar
  88. 88.
    Carr DB, Goate A, Phil D, et al. Current concepts in the pathogenesis of Alzheimer’s disease. Am J Med 1997; 103(3A): 3S–10SPubMedCrossRefGoogle Scholar
  89. 89.
    Breitner JC, Gau BA, Welsh KA, et al. Inverse association of anti-inflammatory treatments and Alzheimer’s disease: initial results of a co-twin control study. Neurology 1994; 44(2): 227–32PubMedCrossRefGoogle Scholar
  90. 90.
    Halliday GM, Shepherd CE, McCann H, et al. Effect of anti-inflammatory medications on neuropathological findings in Alzheimer disease. Arch Neurol 2000; 57(6): 831–6PubMedCrossRefGoogle Scholar
  91. 91.
    Palinski W. Immunomodulation: a new role for statins? Nat Med 2000; 6(12): 1311–2PubMedCrossRefGoogle Scholar
  92. 92.
    Kwak B, Mulhaupt F, Myit S, et al. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6(12): 1399–402PubMedCrossRefGoogle Scholar
  93. 93.
    Simons M, Keller P, De Strooper B, et al. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 1998; 95(11): 6460–4PubMedCrossRefGoogle Scholar
  94. 94.
    Kilsdonk EP, Yancey PG, Stoudt GW, et al. Cellular cholesterol efflux mediated by cyclodextrins. J Biol Chem 1995; 270(29): 17250–6PubMedCrossRefGoogle Scholar
  95. 95.
    Kritharides L, Kus M, Brown AJ, et al. Hydroxypropyl-beta-cyclodextrin-mediated efflux of 7-ketocholesterol from macrophage foam cells. J Biol Chem 1996; 271(44): 27450–5PubMedCrossRefGoogle Scholar
  96. 96.
    Wolozin B, Kellman W, Ruosseau P, et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000; 57(10): 1439–43PubMedCrossRefGoogle Scholar
  97. 97.
    Tsuji A, Saheki A, Tamai I, et al. Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier. J Pharmacol Exp Ther 1993; 267 (3): 1085–90Google Scholar
  98. 98.
    Saheki A, Terasaki T, Tamai I, et al. In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3- methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm Res 1994; 11(2): 305–11PubMedCrossRefGoogle Scholar
  99. 99.
    Quion JA, Jones PH. Clinical pharmacokinetics of pravastatin. Clin Pharmacokinet 1994; 27(2): 94–103PubMedCrossRefGoogle Scholar
  100. 100.
    Wolozin B. Letter. Arch Neurol 2001; 58: 1023CrossRefGoogle Scholar
  101. 101.
    Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia. Lancet 2000; 356(9242): 1627–31PubMedCrossRefGoogle Scholar
  102. 102.
    Friedhoff LT, Cullen EI, Geoghagen NS, et al. Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide. Int J Neuropsychopharmacol 2001; 4(2): 127–30PubMedCrossRefGoogle Scholar
  103. 103.
    Muldoon MF, Barger SD, Ryan CM, et al. Effects of lovastatin on cognitive function and psychological well-being. Am J Med 2000; 108(7): 538–46PubMedCrossRefGoogle Scholar
  104. 104.
    Shepherd J, Blauw GJ, Murphy MB, et al. The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Am J Cardiol 1999; 84(10): 1192–7PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2003

Authors and Affiliations

  1. 1.Department of Cardiology, Concord HospitalUniversity of SydneyConcordAustralia
  2. 2.Centre for Thrombosis and Vascular ResearchUniversity of New South WalesAustralia

Personalised recommendations